S 230815
Alternative Names: KCNT1 ASO; S-230815Latest Information Update: 01 Jul 2026
At a glance
- Originator Servier
- Class Antiepileptic drugs; Antisense oligonucleotides
- Mechanism of Action KCNT1 protein expression modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Epilepsy
Most Recent Events
- 25 Jun 2026 Phase-I/II clinical trials in Epilepsy (In children, In infants, In adolescents, In neonates) in USA, Japan (Intrathecal) (NCT07227857)
- 21 Nov 2025 Phase-I/II clinical trials in Epilepsy (In neonates, In infants, In children, In adolescents) in France (Intrathecal) (CTIS2024-513332-17-00)
- 19 Nov 2025 Phase-I/II clinical trials in Epilepsy (In neonates, In infants, In children, In adolescents) in Spain (Intrathecal) (CTIS2024-513332-17-00)